Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Drill Results

Microbix Presents Reference-Material Innovations at EUROGIN

MBX · Price

Executive Summary

  • Microbix Biosystems announced the introduction of novel “normalized” viral‑load reference materials within its QUANTDx™ line to improve validation of HPV molecular assays.
  • The company will present these results at the EUROGIN conference in Vienna (Mar 18‑21, 2026) via a poster titled “Novel HPV Reference Materials Representing Normalized Viral Load for Use in Assay Validation.”
  • The new materials enable assay developers to assess limit of detection, sensitivity and specificity across varied sample adequacy scenarios, supporting regulatory submissions and faster qualification of new specimen formats.

Key Details

  • Product Scope: QUANTDx™ now includes >80 reference materials covering six disease panels (fungal, gastrointestinal, HPV, meningitis, respiratory, STI).
  • HPV Innovation: Materials are “normalized” – viral genome copies are expressed relative to human cell count, allowing assessment of sample adequacy and differentiation of latent vs. active infection states.
  • Assay Performance Metrics Enabled: Limit of detection (LoD), positive accuracy (sensitivity), negative accuracy (specificity).
  • Regulatory Relevance: Supports data packages for regulatory submissions by providing traceable, quantified standards.
  • Conference Presentation: Poster to be displayed at EUROGIN (Vienna, Austria) 18‑21 Mar 2026; poster will later be available online at https://microbix.com.
  • Collaborators & Authors: External collaborators – Katherine Lutz and Larry Vaughn (BD Life Sciences); internal staff authors – Pavel Zhelev, Sydney Rivers, Amer Alagic, Jieran Li, Connor Randall.
  • Market Need Highlighted: Normalized HPV reference materials are currently scarce among ISO‑accredited third‑party providers; Microbix’s offering fills this gap.
  • Application Scenarios: Validation of new sample formats (first‑void urine, self‑collected swabs) and assessment of how variations in sample quality/quantity affect assay outcomes.
  • Commercial Availability: Purchase inquiries directed to [email protected]; product information at https://microbix.com/products/reference-materials/.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from MICROBIX BIOSYSTEMS INC. J